Abstract:Abstract Background: Biliary tract cancer (BTC), including intra- or extrahepatic cholangiocarcinoma (CCA) and gallbladder cancer, is an aggressive malignancy with limited treatment options. Most patients (pts) present with advanced or unresectable disease, for which the current first-line standard of care is gemcitabine with cisplatin. Prognosis for these pts is poor, with median survival of approximately 12 months. Pembrolizumab (pembro) has improved outcomes when combined with platinum-based chemotherapy in other tumor types (eg, gastric/GEJ, NSCLC). The randomized, placebo-controlled, double-blind, phase 3 KEYNOTE-966 trial (NCT04003636) will be conducted to evaluate pembro plus gemcitabine and cisplatin compared with placebo plus gemcitabine and cisplatin in pts with metastatic or unresectable locally advanced BTC. Methods: Pts will be randomly assigned 1:1 to receive pembro 200 mg or placebo IV every 3 weeks plus gemcitabine 1000 mg/m2 IV and cisplatin 25 mg/m2 IV on days 1 and 8 of every 3-week cycle. Cisplatin will be given for a maximum of 8 cycles. Treatment with pembro/placebo will continue for up to 35 administrations or until disease progression, unacceptable toxicity, or withdrawal from the study. Gemcitabine will be continued until disease progression, unacceptable toxicity, or withdrawal from the study. Pts will be stratified by region (Asia, non-Asia), stage (locally advanced, metastatic), and site of origin (gallbladder, intrahepatic CCA, or extrahepatic CCA). Key eligibility criteria are age ≥18 years; histologically confirmed metastatic or unresectable locally advanced BTC, measurable by RECIST v1.1; no prior systemic therapy for advanced BTC; Eastern Cooperative Oncology Group performance status of 0 or 1; and tumor sample adequate for biomarker analyses. Pts with past or ongoing hepatitis C or controlled hepatitis B virus infection are eligible per protocol-defined criteria. During the initial stage, response will be assessed by imaging every 6 weeks until week 54 and every 12 weeks thereafter. Safety, assessed by CTCAE v.5.0, will be monitored throughout the study and for 30 days after treatment end or 90 days for serious adverse events. The primary end points are progression-free survival (as assessed by blinded independent central review) and overall survival (OS). Secondary end points are objective response rate, duration of response, and safety. Additional analyses will include disease control rate, health-related quality of life (by EORTC QLQ-C30, EuroQol EQ-5D, and EORTC QLQ-BIL21), and molecular and genetic biomarkers. The study opened to recruitment on September 24, 2019. Recruitment is underway in 17 countries and will continue until approximately 788 pts are enrolled. Citation Format: Richard S. Finn, Robin K. Kelley, Junji Furuse, Julien Edeline, Zhenggang Ren, Shu-Chih Su, Usha Malhotra, Abby B. Siegel, Juan W. Valle. KEYNOTE-966: A randomized, double-blind, placebo-controlled, phase 3 study of pembrolizumab in combination with gemcitabine and cisplatin for the treatment of advanced biliary tract carcinoma [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT283.

A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study

A Single-Arm Phase II Study of Nab-Paclitaxel Plus Gemcitabine and Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancer.

Multicenter phase I/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer

Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population

P5-5 Phase 2/3 Study of Bintrafusp Alfa with Gemcitabine Plus Cisplatin As First-Line Treatment of Biliary Tract Cancer

AB052. P-20. Phase 2, Open-Label Study of Second-Line M7824 Treatment in Patients with Locally Advanced or Metastatic Biliary Tract Cancer

Preoperative Chemotherapy Prior to Primary Tumor Resection for Asymptomatic Synchronous Unresectable Colorectal Liver-Limited Metastases: A Multicenter Randomized Controlled Trial.

Efficacy and Biomarker Analysis of Nivolumab Plus Gemcitabine and Cisplatin in Patients with Unresectable or Metastatic Biliary Tract Cancers: Results from a Phase II Study

Abstract CT283: KEYNOTE-966: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Pembrolizumab in Combination with Gemcitabine and Cisplatin for the Treatment of Advanced Biliary Tract Carcinoma

A Phase 3, Randomized Study of Adjuvant Rilvegostomig Plus Chemotherapy in Resected Biliary Tract Cancer: ARTEMIDE-Biliary01.

78Tip KEYNOTE-966 Trial in Progress: Pembrolizumab Plus Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer

Nab-paclitaxel plus anti–PD-1 antibody as second-line treatment for advanced biliary tract cancer: An investigator-initiated phase 2 study (NapaSinti trial).

Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study

A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center Munich

Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study

Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments

Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma

Adjuvant Chemotherapy with Gemcitabine and Cisplatin Compared to Observation after Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gallbladder Carcinoma (ACTICCA-1): A Randomized, Multidisciplinary, Multinational Phase III Trial.

Treatment patterns of gemcitabine-based chemotherapy in patients with de novo and recurrent advanced biliary tract cancer.

Adjuvant Tislelizumab Combined with Capecitabine for Patients with Biliary Tract Cancer with High Risk of Postoperative Relapse (ACTIVE): Primary Analysis from a Prospective Cohort Study.